var data={"title":"Alendronate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Alendronate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5583?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=alendronate-drug-information\" class=\"drug drug_general\">see &quot;Alendronate: Drug information&quot;</a> and <a href=\"topic.htm?path=alendronate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Alendronate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131404\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Binosto;</li>\n      <li>Fosamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131405\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fosamax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996597\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Bisphosphonate Derivative</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996629\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=alendronate-drug-information\" class=\"drug drug_general\">see &quot;Alendronate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteogenesis imperfecta:</b> Limited data available, dosing regimens and efficacy results variable (Akcay 2008; Pizones 2005; Seikaly 2005; Ward 2011): Children &ge;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;30 kg: Oral: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">30 to &lt;40 kg: 5 or 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;40 kg: Oral: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on several prospective and retrospective trials; most smaller studies reported increased bone mineral density (BMD), decreased frequency of fractures, alleviation of chronic pain, and in some patients increased mobility (Akcay 2008; Pizones 2005; Seikaly2005; Unal 2005; Vyskocil 2005). The largest trial, a multicenter, randomized, placebo-controlled trial (n= 109 in treatment group, n=83 completed 2-year follow-up) reported significant increases in lumbar spine BMD; however, other efficacy markers including long-bone fracture rate and pediatric disability score were no different than placebo (Ward 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteopenia associated with cystic fibrosis (CF): </b>Limited data available: Children &ge;5 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;25 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;25 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on a randomized, placebo-controlled trial of CF patients (n= 128, treatment group: n=65) with low apparent BMD age and inadequate response to calcium and calcifediol treatment; results showed a significant increase in BMD (16.3% vs 3.1% from baseline); evaluation of effect on fracture rate not possible due to sample size and duration (trial duration: 2 years); alendronate appeared to be well-tolerated with no notable difference in adverse effects reported (Bianchi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteopenia, nonambulatory patients (eg, cerebral palsy, muscular dystrophy):</b> Limited data available, efficacy results variable: <b>Note</b>: Due to added complexity of administration requirements (eg, remaining in an upright position for an extended time) weekly dosing is preferred in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing (Apkon 2008; Houston 2014; Sholas 2005): Children &ge;6 years and Adolescents: Oral: Usual reported dose: 35 mg once <b>weekly. </b>Dosing based on experience in 42 patients (age range: 6 to 16 years) from two case series and a retrospective trial. In the retrospective cohort study (n=29 mean age: 12 years), treatment showed a non-statistically significant trend in Z-score stabilization (Houston 2014). A case series of 10 patients (age range: 6 to 16 years) reported fewer fractures after treatment started compared to the prior year; alendronate was reported as being well tolerated; one patient discontinued therapy for hematemesis (also receiving high-dose ibuprofen therapy) (Sholas 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children &ge;3 years and Adolescents: Oral: 1 mg/kg/dose once <b>weekly </b>(Paksu 2012)<b>; </b>if using a solid dosage form, consider dose rounding to the nearest 10 mg (up or down as appropriate) (Lethaby 2007). Dosing based on a prospective trial of 26 patients (age range: 3 to 17 years); results showed after one year of treatment, increased BMD and decreased alkaline phosphatase.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteopenia/Osteoporosis, rheumatology patients (eg, JIA, SLE, dermatomyositis)</b>: Limited data available: Children &ge;4 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;20 kg: Oral: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;20 kg to 30 kg: Oral: 5 or 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;30 kg: Oral: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on a prospective trial (multicenter and single center) (Bianchi 2000; Cimaz 2002; Unal 2006); results from trials showed bone mineral density (BMD) was significantly increased (to normal values in some patients) after alendronate therapy; in some cases, bone turnover markers were reduced without a reduction of inflammatory activity (underlying rheumatologic disease process)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Consider discontinuing after 3 to 5 years of use for osteoporosis in patients at low-risk for fracture. Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis in postmenopausal females:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis: Oral: 5 mg once daily <b>or</b> 35 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Oral: 10 mg once daily <b>or</b> 70 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis in males:</b> Treatment: Oral: 10 mg once daily <b>or</b> 70 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoporosis secondary to glucocorticoids in males and females:</b> Treatment: Oral: 5 mg once daily; a dose of 10 mg once daily should be used in postmenopausal females who are not receiving estrogen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Paget disease of bone in males and females:</b> Oral: 40 mg once daily for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Retreatment: Following a 6-month post-treatment evaluation period, retreatment with alendronate may be considered in patients who have relapsed based on increases in serum alkaline phosphatase, which should be measured periodically. Retreatment may also be considered in those who failed to normalize their serum alkaline phosphatase. The Endocrine Society guidelines suggest re-treatment may be required between 2 and 6 years (Singer 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Missed doses (once weekly):</i> If a once-weekly dose is missed, it should be given the next morning after remembered; may then return to the original once-weekly schedule (original scheduled day of the week); however, do not give 2 doses on the same day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;35 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;35 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131381\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 70 mg/75 mL (75 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosamax: 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Effervescent, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Binosto: 70 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131366\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11441253\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Binosto: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WgPWVrnoP6kIShdNGV+r9fQ==&amp;TOPIC_ID=114896\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Fosamax: http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_mg.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996635\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication of the day. Do not take with mineral water or with other beverages. Remain upright (do not lie down) for at least 30 minutes <b>and</b> until after first food of the day (to reduce esophageal irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Follow administer of oral solution with at least 2 oz of plain water.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet (Fosamax): Must be taken with 6 to 8 oz of plain water. The tablet should be swallowed whole; do not chew or suck on the tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, effervescent (Binosto): Dissolve one tablet in 4 oz of room temperature plain water only; once effervescence stops, wait &ge;5 minutes and stir the solution for ~10 seconds and then drink</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131399\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Do not freeze.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet (Fosamax): Store at room temperature of 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep in well-closed container.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, effervescent (Binosto): Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from moisture. Store in original blister package until use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996598\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of osteoporosis (Binosto, Fosamax: FDA approved in postmenopausal females and adult males); prevention of osteoporosis (Fosamax: FDA approved in postmenopausal females); treatment of Paget disease of the bone in patients who are symptomatic, at risk for future complications, or with alkaline phosphatase &ge;2 times the upper limit of normal (Fosamax: FDA approved in adults); treatment of glucocorticoid-induced osteoporosis in patients with low bone mineral density who are receiving a daily dosage &ge;7.5 mg of prednisone (or equivalent) (Fosamax: FDA approved in adults); has also been used in the treatment of osteogenesis imperfect and osteopenia in cystic fibrosis, nonambulatory (eg, cerebral palsy), and rheumatology patients</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131431\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alendronate may be confused with risedronate</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fosamax may be confused with Flomax, Fosamax Plus D, fosinopril, Zithromax</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Fosamax  [US, Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131429\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Decreased serum calcium (transient, mild), decreased serum phosphate (transient, mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal distension, abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, dysphagia, esophageal ulcer, flatulence, gastric ulcer (may be severe with complications), gastritis, gastroesophageal reflux disease, melena, nausea   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle cramps, musculoskeletal pain (includes bone pain, joint pain, and muscle pain) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Alopecia, cholesteatoma, conjunctivitis, duodenal ulcer (may be severe with complications), dysgeusia, episcleritis, erythema, erosive esophagitis, esophageal perforation, esophageal stenosis, esophageal ulcer, esophagitis, exacerbation of asthma, femur fracture (low energy fractures, including subtrochanteric and diaphyseal), hypersensitivity reaction (includes angioedema and urticaria), hypocalcemia (symptomatic), joint swelling, malaise, oropharyngeal ulcer, osteonecrosis of the jaw (generally associated with tooth extraction and/or local infection with delayed healing), peripheral edema, scleritis, skin rash (occasionally with photosensitivity), Stevens-Johnson syndrome, toxic epidermal necrolysis, uveitis, vertigo, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131388\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to alendronate, other bisphosphonates, or any component of the formulation; hypocalcemia; abnormalities of the esophagus (eg, stricture, achalasia) which delay esophageal emptying; inability to stand or sit upright for at least 30 minutes; increased risk of aspiration (effervescent tablets; oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Renal insufficiency with creatinine clearance &lt;35 mL/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131370\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone fractures: Atypical femur fractures (AFF) have been reported in patients receiving bisphosphonates. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures; atypical femur fractures have also been reported in patients not taking bisphosphonates, and in patients receiving glucocorticoids. Patients receiving long-term (&gt;3 to 5 years) bisphosphonate therapy may be at an increased risk (Adler 2016; NOF [Cosman 2014]); however, benefits of therapy (when used for osteoporosis) generally outweigh absolute risk of AFF within the first 5 years of treatment (Adler 2016). Patients presenting with thigh or groin pain with a history of receiving bisphosphonates should be evaluated for femur fracture. Consider interrupting bisphosphonate therapy in patients who develop a femoral shaft fracture; assess for fracture in the contralateral limb.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone/joint/muscle pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Hypocalcemia has been reported with the use of bisphosphonates. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Conjunctivitis, uveitis, episcleritis, and scleritis have been reported with alendronate; patients presenting with signs of ocular inflammation may require further ophthalmologic evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ), also referred to as medication-related osteonecrosis of the jaw (MRONJ), has been reported in patients receiving bisphosphonates. Known risk factors for MRONJ include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery), cancer diagnosis, concomitant therapy (eg, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, ill-fitting dentures, and comorbid disorders (anemia, coagulopathy, infection, preexisting dental or periodontal disease). Risk may increase with increased duration of bisphosphonate use. According to a position paper by the American Association of Maxillofacial Surgeons (AAOMS), MRONJ has been associated with bisphosphonate and other antiresorptive agents (denosumab), and antiangiogenic agents (eg, bevacizumab, sunitinib) used for the treatment of osteoporosis or malignancy; risk of MRONJ is significantly higher in cancer patients receiving antiresorptive therapy compared to patients receiving osteoporosis treatment (regardless of medication used or dosing schedule). MRONJ risk is also increased with intravenous antiresorptive use compared to the minimal risk associated with oral bisphosphonate use, although risk appears to increase with oral bisphosphonates when duration of therapy exceeds 4 years (AAOMS [Ruggiero 2014]). The manufacturer's labeling states that in patients requiring invasive dental procedures, discontinuing bisphosphonates may reduce the risk of ONJ and clinical judgment should guide the decision. However, the AAOMS suggests there is currently no evidence that interrupting oral bisphosphonate therapy alters the risk of ONJ following tooth extraction, and that in patients receiving oral bisphosphonates for &lt;4 years who have no clinical risk factors, no alternations or delay in any procedure common to oral/maxillofacial surgeons, periodontists, and other dental providers is necessary (special considerations apply to patients receiving dental implants). Conversely, in patients receiving oral bisphosphonates for &gt;4 years <b>or</b> in patients receiving oral bisphosphonates for &lt;4 years who have also taken corticosteroids or antiangiogenic medications concomitantly, the AAOMS recommends considering a 2-month, drug-free period prior to invasive dental procedures (recommendation based on a theoretical benefit). Patients developing ONJ during therapy should receive care by an oral surgeon (AAOMS [Ruggiero 2014]). According to the manufacturer, discontinuation of the bisphosphonate therapy should be considered (based on risk/benefit evaluation) in patients who develop ONJ.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (not recommended for use in patients with CrCl &lt;35 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effervescent tablet: Each effervescent tablet contains 650 mg of sodium (NaCl 1650 mg). Use with caution in patients following a sodium-restricted diet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50586614\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The potential adverse effects of bisphosphonate therapy on the immature bones of growing children are concerning and data to fully describe are insufficient. Animal data has shown alendronate (high-dose) inhibits longitudinal bone growth (Rauch 2004); pediatric patients with osteogenesis imperfecta (OI) treated with pamidronate for 4 years showed increased height z scores (Zeitlin 2003); pediatric growth effects with other bisphosphonates is lacking. Possible decreased bone remodeling affecting growth or fracture healing may occur with bisphosphonate therapy; a case-report in an adolescent treated with high-dose pamidronate described abnormal long-bone modeling (Rauch 2004); a large, placebo-controlled OI trial (n=109, age range: 4 to 19 years) reported that alendronate did not interfere with fracture healing (Ward 2011). Rapid and in some cases significant weight gain has been reported with pamidronate therapy in pediatric patients which may negatively affect rehabilitation in patients with OI (Zeitlin 2003). Monitor patients closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298701\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131375\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=114896&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiogenesis Inhibitors (Systemic): May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Specifically, the risk for osteonecrosis of the jaw may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Magaldrate; Sodium Bicarbonate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Alendronate. Specifically, the incidence of upper gastrointestinal adverse events may be increased<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parathyroid Hormone: Alendronate may diminish the therapeutic effect of Parathyroid Hormone. More specifically, Alendronate may interfere with normalization of blood calcium concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131400\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">All food and beverages interfere with absorption. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice, coffee, and mineral water) and food may reduce the absorption of alendronate as much as 60%. Management: Alendronate must be taken first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication of the day.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131377\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131391\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. It is not known if bisphosphonates cross the placenta, but fetal exposure is expected (Djokanovic 2008; Stathopoulos 2011). Bisphosphonates are incorporated into the bone matrix and gradually released over time. The amount available in the systemic circulation varies by dose and duration of therapy. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy; however, available data have not shown that exposure to bisphosphonates during pregnancy significantly increases the risk of adverse fetal events (Djokanovic 2008; Levy 2009; Stathopoulos 2011). Until additional data is available, most sources recommend discontinuing bisphosphonate therapy in women of reproductive potential as early as possible prior to a planned pregnancy; use in premenopausal women should be reserved for special circumstances when rapid bone loss is occurring (Bhalla 2010; Pereira 2012; Stathopoulos 2011). Because hypocalcemia has been described following in utero bisphosphonate exposure, exposed infants should be monitored for hypocalcemia after birth (Djokanovic 2008; Stathopoulos 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F996637\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteogenesis imperfecta: In pediatric trials, serum calcium and phosphorus, alkaline phosphatase, urinary calcium/creatinine ratio every 3 months; bone mineral density (DEXA) at baseline and periodically with therapy (eg, every 6 to 12 months); annual skeletal survey (Akcay 2008; Seikaly 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cystic fibrosis: Based on expert recommendations and in pediatric trial experience, growth parameters (eg, height, weight, z-scores, etc) at baseline and periodically with therapy; bone mineral density (lumber; baseline and every 6 months or annually) (Aris 2005; Bianchi 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osteopenia/Osteoporosis: Bone mineral density, number and location of fractures, height and weight, pain; serum calcium and 25(OH)D; alkaline phosphatase, biochemical markers of bone turnover</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paget disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131369\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131387\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 28 L (exclusive of bone)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~78%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Fasting:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;4 years and Adolescents: Mean range: 0.41% to 0.56% (Nakhla 2011; Ward 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 0.6%; reduced up to 60% with coffee or orange juice</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Exceeds 10 years</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; feces (as unabsorbed drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131390\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Alendronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg/75 mL (75 mL): $57.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, effervescent</b> (Binosto Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (1): $57.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Alendronate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $292.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $87.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">35 mg (4): $81.95</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $197.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (4): $81.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Fosamax Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">70 mg (4): $153.41</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F131393\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adronat (AU, IT, PT);</li>\n      <li>Albinax (VN);</li>\n      <li>Aldren 70 (PH, TH);</li>\n      <li>Aldron (HR);</li>\n      <li>Aldrox (CL);</li>\n      <li>Alenato (AR);</li>\n      <li>Alend (KR);</li>\n      <li>Alendomax (JO);</li>\n      <li>Alendovenir (IL);</li>\n      <li>Alendra (PH);</li>\n      <li>Alendrate (NZ);</li>\n      <li>Alendrex (NZ);</li>\n      <li>Alendro (AU, LK, SA);</li>\n      <li>Alendro Once Weekly (KW);</li>\n      <li>Alendrobell (AU);</li>\n      <li>Alendronate (TH);</li>\n      <li>Alendros (KR);</li>\n      <li>Alendroxl (PH);</li>\n      <li>Alenfos (KR);</li>\n      <li>Alenfosa (VN);</li>\n      <li>Allentop (HK);</li>\n      <li>Alnate (LK);</li>\n      <li>Alovell (ID, PH, VN);</li>\n      <li>Arendal (PE);</li>\n      <li>Armol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Bifosa (IN);</li>\n      <li>Bisbon (KR);</li>\n      <li>Bonafide (LK);</li>\n      <li>Bonaid (KR);</li>\n      <li>Bonalon (JP);</li>\n      <li>Bonamax (QA);</li>\n      <li>Bonapex (EG);</li>\n      <li>Bonmax (JO);</li>\n      <li>BonMax (TH);</li>\n      <li>Calidron (JO);</li>\n      <li>Densate (AU);</li>\n      <li>Drate (LK);</li>\n      <li>Endronax (BR);</li>\n      <li>Fonat (AU);</li>\n      <li>Forosa (PH);</li>\n      <li>Fosalan (IL);</li>\n      <li>Fosamax (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, GY, HR, IE, IT, JM, JO, KR, KW, LB, LK, LU, MT, MX, NL, NO, NZ, PE, PK, PL, PR, PT, QA, RO, RU, SA, SE, SG, SI, SK, SR, TR, TT, TW, VE, VN);</li>\n      <li>Fosamax Once Weekly (AE, BH, HK, LB, SA);</li>\n      <li>Fosmin (EC, PE);</li>\n      <li>Fostepor (IE);</li>\n      <li>Fostolin (IE);</li>\n      <li>Fosval (PY);</li>\n      <li>Gendarin (SE);</li>\n      <li>Gubang (CN);</li>\n      <li>Kalosten (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Lendomax (AE);</li>\n      <li>Malend (KR);</li>\n      <li>Marvil (LB, PE, UY);</li>\n      <li>MaxiBone (IL);</li>\n      <li>MaxiBone 70 (IL);</li>\n      <li>Maxlen (TH);</li>\n      <li>Nichospor (ID);</li>\n      <li>Oseomax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Oseotenk (AR);</li>\n      <li>Osficar (CO);</li>\n      <li>Ossmax (AU);</li>\n      <li>Osteo-Plus (PH);</li>\n      <li>Osteocor (PH);</li>\n      <li>Osteodron (PH);</li>\n      <li>Osteofar (ID);</li>\n      <li>Osteofos (HK, IN);</li>\n      <li>Osteol (PY);</li>\n      <li>Osteomax (PH);</li>\n      <li>Osteomel (IE);</li>\n      <li>Osteopor (UY);</li>\n      <li>Osteosan (CL);</li>\n      <li>Osteovan (CR);</li>\n      <li>Osteve (LB, QA);</li>\n      <li>Ostex (CO);</li>\n      <li>Osto (LK);</li>\n      <li>Porosal (VE);</li>\n      <li>Reventa (PH);</li>\n      <li>Romax (IE);</li>\n      <li>Tevanate (BG, TW);</li>\n      <li>Valora (HR);</li>\n      <li>Zeroclast (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akcay T, Turan S, Guran T, Bereket A. Alendronate treatment in children with osteogenesis imperfecta. <i>Indian Pediatr</i>. 2008;45(2):105-109<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/18310788/pubmed\" target=\"_blank\" id=\"18310788\">18310788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alendronate solution [prescribing information]. South Beloit, IL: TAGI Pharma, Inc.; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Apkon S, Coll J. Use of weekly alendronate to treat osteoporosis in boys with muscular dystrophy. <i>Am J Phys Med Rehabil</i>. 2008;87(2):139-143.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17912140/pubmed\" target=\"_blank\" id=\"17912140\">17912140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhalla AK, &quot;Management of Osteoporosis in a Pre-menopausal Woman,&quot; <i>Best Pract Res Clin Rheumatol</i>, 2010, 24(3):313-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bianchi ML, Cimaz R, Bardare M, et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. <i>Arthritis Rheum</i>. 2000;43(9):1960-1966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/11014345/pubmed\" target=\"_blank\" id=\"11014345\">11014345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bianchi ML, Colombo C, Assael BM, et al. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate. <i>Lancet Respir Med</i>. 2013;1(5):377-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20534366/pubmed\" target=\"_blank\" id=\"20534366\">20534366</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonisto tablets (alendronate) [prescribing information]. San Antonio, TX: Mission Pharmacal Company; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cimaz R, Gattorno M, Sormani MP, et al. Changes in markers of bone turnover and inflammatory variables during alendronate therapy in pediatric patients with rheumatic diseases. <i>J Rheumatol</i>. 2002;29(8):1786-1792.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/12180745/pubmed\" target=\"_blank\" id=\"12180745\">12180745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Djokanovic N, Klieger-Grossmann C, and Koren G, &quot;Does Treatment With Bisphosphonates Endanger the Human Pregnancy?&quot; <i>J Obstet Gynaecol Can</i>, 2008, 30(12):1146-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19175968/pubmed\" target=\"_blank\" id=\"19175968\">19175968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fosamax tablets (alendronate) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; March 2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20508948/pubmed\" target=\"_blank\" id=\"20508948\">20508948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houston C, Mathews K, Shibli-Rahhal A. Bone density and alendronate effects in Duchenne muscular dystrophy patients. <i>Muscle Nerve</i>. 2014;49(4):506-511.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/23835890/pubmed\" target=\"_blank\" id=\"23835890\">23835890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kotecha RS, Powers N, Lee SJ, Murray KJ, Carter T, Cole C. Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). <i>Pediatr Blood Cancer</i>. 2010;54(7):934-940.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/20127847/pubmed\" target=\"_blank\" id=\"20127847\">20127847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lethaby C, Wiernikowski J, Sala A, Naronha M, Webber C, Barr RD. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience. <i>J Pediatr Hematol Oncol</i>. 2007;29(9):613-616.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/17805035/pubmed\" target=\"_blank\" id=\"17805035\">17805035</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy S, Fayez I, Taguchi N, et al, &quot;Pregnancy Outcome Following <i>in utero</i> Exposure to Bisphosphonates,&quot; <i>Bone</i>, 2009, 44(3):428-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/19059370/pubmed\" target=\"_blank\" id=\"19059370\">19059370</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nakhla M, Denker AE, Connor JD, et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. <i>Clin Ther</i>. 2011;33(10):1516-1523.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21962451/pubmed\" target=\"_blank\" id=\"21962451\">21962451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Paksu MS, Vurucu S, Karaoglu A, et al. Osteopenia in children with cerebral palsy can be treated with oral alendronate. <i>Childs Nerv Syst</i>. 2012;28(2):283-286.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21928064/pubmed\" target=\"_blank\" id=\"21928064\">21928064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pereira RM, Carvalho JF, Paula AP, et al, &quot;Guidelines for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis,&quot; <i>Rev Bras Reumatol</i>, 2012, 52(4):580-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22885424/pubmed\" target=\"_blank\" id=\"22885424\">22885424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pizones J, Plotkin H, Parra-Garcia JI, et al. Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. <i>J Pediatr Orthop</i>. 2005;25(3):332-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/15832149/pubmed\" target=\"_blank\" id=\"15832149\">15832149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. <i>J Clin Endocrinol Metab</i>. 2006;91(2):511-516.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16291701/pubmed\" target=\"_blank\" id=\"16291701\">16291701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruggiero SL, Dodson TB, Fantasia J, et al; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. <i>J Oral Maxillofac Surg</i>. 2014;72(10):1938-1956. doi: 10.1016/j.joms.2014.04.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25234529/pubmed\" target=\"_blank\" id=\"25234529\">25234529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. <i>J Pediatr Orthop</i>. 2005;25(6):786-791.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16294137/pubmed\" target=\"_blank\" id=\"16294137\">16294137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sholas MG, Tann B, Gaebler-Spira D. Oral bisphosphonates to treat disuse osteopenia in children with disabilities: a case series. <i>J Pediatr Orthop</i>. 2005;25(3):326-331.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/15832148/pubmed\" target=\"_blank\" id=\"15832148\">15832148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer FR, Bone HG, Hosking DJ, et al. Paget's disease of bone: an Endocrine Society practice guideline. <i>J Clin Endocrinol Metab</i>. 2014;99(12):4408-4422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/25406796/pubmed\" target=\"_blank\" id=\"25406796\">25406796</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stathopoulos IP, Liakou CG, Katsalira A, et al, &quot;The Use of Bisphosphonates in Women Prior to or During Pregnancy and Lactation,&quot; <i>Hormones (Athens)</i>, 2011, 10(4):280-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/22281884/pubmed\" target=\"_blank\" id=\"22281884\">22281884</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tragiannidis A, Athanassiadou F, Papageorgiou T, Petsatodis G. Severe skeletal complications in a child with acute lymphoblastic leukemia. <i>Pediatr Hematol Oncol</i>. 2006;23(6):523-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16849284/pubmed\" target=\"_blank\" id=\"16849284\">16849284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unal E, Abaci A, Bober E, B&uuml;y&uuml;kgebiz A. Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis. <i>J Pediatr Endocrinol Metab</i>. 2006;19(4):523-528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16759038/pubmed\" target=\"_blank\" id=\"16759038\">16759038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Unal E, Abaci A, Bober E, Buyukgebiz A. Oral alendronate in osteogenesis imperfecta. <i>Indian Pediatr</i>. 2005;42(11):1158-1160.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16340059/pubmed\" target=\"_blank\" id=\"16340059\">16340059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vyskocil V, Pikner R, Kut&iacute;lek S. Effect of alendronate therapy in children with osteogenesis imperfecta. <i>Joint Bone Spine</i>. 2005;72(5):416-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16214075/pubmed\" target=\"_blank\" id=\"16214075\">16214075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ward LM, Rauch F, Whyte MP, et al. Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. <i>J Clin Endocrinol Metab</i>. 2011;96(2):355-364.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/21106710/pubmed\" target=\"_blank\" id=\"21106710\">21106710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiernikowski JT, Barr RD, Webber C, Guo CY, Wright M, Atkinson SA. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study. <i>J Oncol Pharm Pract</i>. 2005;11(2):51-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/alendronate-pediatric-drug-information/abstract-text/16460605/pubmed\" target=\"_blank\" id=\"16460605\">16460605</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 114896 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F131404\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F131405\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F996597\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F996629\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F131381\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F131366\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11441253\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F996635\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F131399\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F996598\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F131431\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F131429\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F131388\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F131370\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50586614\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298701\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F131375\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F131400\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F131377\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F131391\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F996637\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F131369\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F131387\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F131390\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F131393\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/114896|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=alendronate-drug-information\" class=\"drug drug_general\">Alendronate: Drug information</a></li><li><a href=\"topic.htm?path=alendronate-patient-drug-information\" class=\"drug drug_patient\">Alendronate: Patient drug information</a></li></ul></div></div>","javascript":null}